The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Min Yuan; Li-Li Huang; Jian-Hua Chen; Jie Wu; Qing Xu

doi:10.1038/s41392-019-0099-9

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Signal Transduct Target Ther. 2019 Dec 17:4:61. doi: 10.1038/s41392-019-0099-9. eCollection 2019.

Authors

Min Yuan^#^{1

2}, Li-Li Huang^#^{1

2}, Jian-Hua Chen^{1

3}, Jie Wu^{3

4}, Qing Xu^{1

2}

Affiliations

¹ 1Department of Oncology, Dermatology Hospital, Tongji University School of Medicine, Shanghai, 200443 China.
² 2Department of Oncology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072 China.
³ 3Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA.
⁴ 4Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA.

^# Contributed equally.

Abstract

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

Keywords: Lung cancer; Target identification.

Publication types

Review
Research Support, Non-U.S. Gov't